Cytoagents, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.cytoagents.com
Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy
Phase 1
Recruiting
- Conditions
- Cytokine Release Syndrome
- Interventions
- Drug: CTO1681 20 μgDrug: CTO1681 10 μgDrug: CTO1681 30 μg
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- CytoAgents, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT05905328
- Locations
- 🇺🇸
University of California, Irvine - Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath